- 3,753
- 4,198
I think it's perfectly fine for policy to direct priorities to different areas, but that is also not at issue with this case. Bright claims he was dismissed from his position for resisting efforts to fund research into chloroquine and hydroxychloroquine and for limiting the agency from recommending the broad use of the drugs. Typically, when government funds a particular area of research, they leave it to scientists working for the government to decide what particular projects in that area of research merit funding (i.e. merit is decided through a system of peer review run by the NIH, NSF or other agency). Similarly, political figures typically do not interfere with decisions to approve individual drugs, and instead leave these decisions to experts at the FDA (that said, the Obama administration was the first to engage in such interference). The circumstances of Bright's firing seem more akin to these situations than deciding to fund breast cancer research at a higher level than other cancers.russ_watters said:Really? It's nice to say that in principle, but in reality that isn't anywhere close to true. Money spent on disease treatment research is not at all well correlated with scientific concerns. Why is breast cancer so much better funded than other forms of cancer? Because it kills a lot of people? No (it doesn't), because it's a convenient and attractive cause for women and people who want to sell things to women. And maybe because breasts are more attractive than colons.
Minor point:
Breast cancer has the highest incidence of all cancer types in the US accounting for ~ 15% of all new cancer cases (however, it responsible for the third most deaths behind lung cancer and colorectal cancer at 7.0% of cancer deaths). The National Cancer institute spends ~17% of its budget on breast cancer research (the most of any cancer type), which is fairly commensurate with the incidence of the disease (though not the mortality as you point out). If you want a better example of where incidence and funding are out of line, leukemia represents ~3.3% of new cancer cases and 3.8% of deaths but ~8.0% of NCI funding (third behind breast and lung cancer). (This is not to criticize funding of leukemia, however, as there are scientific reasons to justify the funding).